First-Line Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Real-World Outcomes and Prognostic Factors From a Vietnamese Cohort.
Background: Metastatic pancreatic cancer is an aggressive malignancy with limited survival despite intensive chemotherapy. While modified FOLFIRINOX (mFOLFIRINOX) has illustrated efficacy, its real-world data are limited in low-resource healthcare systems. This study evaluated efficacy and toxicity...
| Publicado en: | Clinical Medicine Insights: Oncology Vol. 20; pp. 1 - 9 |
|---|---|
| Autores principales: | , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Sage Publications Inc.
2/25/2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |